$LSTA
LISATA THERAPEUTICS, INC.

2021 Q4 Form 10-Q Financial Statement

#000032001721000108 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.699M $2.843M $2.321M
YoY Change 6.26% 22.49% 12.23%
% of Gross Profit
Research & Development $4.150M $4.125M $3.029M
YoY Change 42.61% 36.18% 0.83%
% of Gross Profit
Depreciation & Amortization $8.000K $14.00K $20.00K
YoY Change -20.0% -30.0% 100.0%
% of Gross Profit
Operating Expenses $6.849M $6.968M $5.350M
YoY Change 25.67% 30.24% 5.48%
Operating Profit -$6.968M -$5.350M
YoY Change 30.24% 5.48%
Interest Expense $40.00K $41.00K $30.00K
YoY Change 36.67%
% of Operating Profit
Other Income/Expense, Net $15.00K $41.00K $25.00K
YoY Change 50.0% 64.0% -85.71%
Pretax Income -$6.794M -$6.927M -$5.325M
YoY Change 25.12% 30.08% 8.74%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.794M -$6.927M -$5.327M
YoY Change 25.12% 30.04% 8.76%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.29
Diluted Earnings Per Share -$113.6K -$0.12 -$0.29
COMMON SHARES
Basic Shares Outstanding 59.78M shares 59.61M shares 18.60M shares
Diluted Shares Outstanding 59.61M shares 18.60M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.97M $100.1M $40.27M
YoY Change 174.69% 148.7% 38.09%
Cash & Equivalents $24.65M $12.77M $21.16M
Short-Term Investments $70.32M $87.38M $19.11M
Other Short-Term Assets $1.212M $1.958M $1.000M
YoY Change 51.5% 95.8% -9.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $96.18M $102.1M $41.26M
YoY Change 172.23% 147.48% 36.42%
LONG-TERM ASSETS
Property, Plant & Equipment $62.00K $70.00K $67.00K
YoY Change 8.77% 4.48% -41.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $764.0K $361.0K $694.0K
YoY Change 24.43% -47.98% -47.1%
Total Long-Term Assets $826.0K $431.0K $761.0K
YoY Change 23.1% -43.36% -46.67%
TOTAL ASSETS
Total Short-Term Assets $96.18M $102.1M $41.26M
Total Long-Term Assets $826.0K $431.0K $761.0K
Total Assets $97.01M $102.5M $42.02M
YoY Change 169.45% 144.03% 32.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.934M $768.0K $1.105M
YoY Change 89.61% -30.5% 30.92%
Accrued Expenses $2.589M $3.304M $3.076M
YoY Change 4.14% 7.41% -40.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.523M $4.072M $4.181M
YoY Change 29.01% -2.61% -30.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $485.0K $53.00K $351.0K
YoY Change 90.94% -84.9% -50.56%
Total Long-Term Liabilities $485.0K $53.00K $351.0K
YoY Change 90.94% -84.9% -50.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.523M $4.072M $4.181M
Total Long-Term Liabilities $485.0K $53.00K $351.0K
Total Liabilities $5.008M $4.125M $4.532M
YoY Change 33.19% -8.98% -32.25%
SHAREHOLDERS EQUITY
Retained Earnings -$453.0M -$446.2M -$420.1M
YoY Change 6.45% 6.21% 1.86%
Common Stock $60.00K $60.00K $19.00K
YoY Change 215.79% 215.79% 90.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $708.0K $708.0K $708.0K
YoY Change 0.0% 0.0% 0.0%
Treasury Stock Shares 11.08K shares 11.08K shares 11.08K shares
Shareholders Equity $92.25M $98.67M $37.74M
YoY Change
Total Liabilities & Shareholders Equity $97.01M $102.5M $42.02M
YoY Change 169.45% 144.03% 32.67%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$6.794M -$6.927M -$5.327M
YoY Change 25.12% 30.04% 8.76%
Depreciation, Depletion And Amortization $8.000K $14.00K $20.00K
YoY Change -20.0% -30.0% 100.0%
Cash From Operating Activities -$4.604M -$5.039M -$3.520M
YoY Change -17.19% 43.15% -20.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $16.46M $4.940M -$11.04M
YoY Change 1708.57% -144.75% -305.2%
Cash From Investing Activities $16.46M $4.940M -$11.05M
YoY Change 1708.57% -144.71% -305.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.00K -64.00K 9.030M
YoY Change 110.0% -100.71%
NET CHANGE
Cash From Operating Activities -4.604M -5.039M -3.520M
Cash From Investing Activities 16.46M 4.940M -11.05M
Cash From Financing Activities 21.00K -64.00K 9.030M
Net Change In Cash 11.87M -163.0K -5.540M
YoY Change -355.93% -97.06% -695.7%
FREE CASH FLOW
Cash From Operating Activities -$4.604M -$5.039M -$3.520M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$4.604M -$5.039M -$3.520M
YoY Change -17.05% 43.15% -20.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000320017
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Type
DocumentType
10-Q
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2021Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33650
dei Entity Registrant Name
EntityRegistrantName
CALADRIUS BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-2343568
dei Entity Address Address Line1
EntityAddressAddressLine1
110 Allen Road, 2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Basking Ridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07920
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
842-0100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CLBS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59779855 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12772000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16512000 USD
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
87377000 USD
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
18061000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1958000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
758000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
102107000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35331000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
361000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
614000 USD
CY2021Q3 us-gaap Assets
Assets
102538000 USD
CY2020Q4 us-gaap Assets
Assets
36002000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
768000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1020000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3304000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2486000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4072000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3506000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
53000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
254000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
4125000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
3760000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 clbs Preferred Stock Liquidation Preference Share
PreferredStockLiquidationPreferenceShare
0.001 shares
CY2021Q3 clbs Preferred Stock Liquidation Preference Share
PreferredStockLiquidationPreferenceShare
0.001 shares
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 clbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2021Q3 clbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59790935 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19389413 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59779855 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19378333 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
60000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
19000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
545601000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
458748000 USD
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
11080 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
11080 shares
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
708000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
708000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-446222000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-425550000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-64000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
98667000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32496000 USD
CY2021Q3 us-gaap Minority Interest
MinorityInterest
-254000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
-254000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98413000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
32242000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102538000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36002000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4125000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3029000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13530000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6346000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2843000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2321000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8671000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7353000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
6968000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
5350000 USD
us-gaap Operating Expenses
OperatingExpenses
22201000 USD
us-gaap Operating Expenses
OperatingExpenses
13699000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6968000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5350000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-22201000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13699000 USD
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
41000 USD
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
25000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
111000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
118000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
41000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
118000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6927000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5325000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13581000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22180000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1508000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10872000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-6927000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-5325000 USD
us-gaap Profit Loss
ProfitLoss
-20672000 USD
us-gaap Profit Loss
ProfitLoss
-2709000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
0 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
2000 USD
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
0 USD
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
10000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6927000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5327000 USD
us-gaap Net Income Loss
NetIncomeLoss
-20672000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2719000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59614000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59614000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18597000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18597000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53811000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53811000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14116000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14116000 shares
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-6927000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-5325000 USD
us-gaap Profit Loss
ProfitLoss
-20672000 USD
us-gaap Profit Loss
ProfitLoss
-2709000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-51000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-47000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-51000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6974000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5339000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-20723000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2723000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
2000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
10000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6974000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5341000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20723000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2733000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
104679000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-6927000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-47000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
708000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98413000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
32242000 USD
us-gaap Profit Loss
ProfitLoss
-20672000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-51000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37487000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20553000 USD
us-gaap Profit Loss
ProfitLoss
-2709000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1391000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
85479000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98413000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33556000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-5325000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
229000 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9032000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-14000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
942000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18715000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37487000 USD
us-gaap Profit Loss
ProfitLoss
-20672000 USD
us-gaap Profit Loss
ProfitLoss
-2709000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1639000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1090000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
47000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
46000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1925000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-172000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1199000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
174000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-252000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-387000 USD
clbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
367000 USD
clbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-2068000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17641000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3256000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
137329000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21819000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
66035000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13646000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71354000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8187000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
248000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
148000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
85479000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18715000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
85255000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18567000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3740000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7124000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16512000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14032000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12772000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21156000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amount of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div>
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
97042000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
96977000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
30750000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
30737000 USD
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9600000 USD
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12676000 USD
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
87377000 USD
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
18061000 USD
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
96977000 USD
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
30737000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis
96979000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
96914000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
63000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
63000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
97042000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
96977000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1811000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1716000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1196000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
400000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3304000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2486000 USD
CY2021Q3 clbs Number Of Offices Under Operating Leases
NumberOfOfficesUnderOperatingLeases
2 office
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
322000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
574000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
322000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
574000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
53000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
254000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
350000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
624000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09625
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
104000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
239000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
27000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
370000 USD
CY2021Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
20000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
350000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65000000 USD
CY2021Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
801148 shares
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1800000 USD
CY2020Q4 clbs Common Stock Warrants Shares
CommonStockWarrantsShares
2638355 shares
CY2020Q4 clbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.18
CY2021Q1 clbs Weighted Average Remaining Contractual Termwarrantoutstanding
WeightedAverageRemainingContractualTermwarrantoutstanding
P4Y11M23D
CY2020Q4 clbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
clbs Warrants Granted
WarrantsGranted
19519393 shares
clbs Weighted Average Exercise Price Warrants Granted
WeightedAverageExercisePriceWarrantsGranted
2.90
clbs Warrants Exercised
WarrantsExercised
801148 shares
clbs Weighted Average Exercise Price Warrants Exercised
WeightedAverageExercisePriceWarrantsExercised
2.19
clbs Warrants Canceled
WarrantsCanceled
0 shares
clbs Weighted Average Exercise Price Warrants Canceled
WeightedAverageExercisePriceWarrantsCanceled
0
clbs Warrants Expired
WarrantsExpired
0 shares
clbs Weighted Average Exercise Price Warrants Expired
WeightedAverageExercisePriceWarrantsExpired
0
CY2021Q3 clbs Common Stock Warrants Shares
CommonStockWarrantsShares
21356600 shares
CY2021Q3 clbs Aggregate Intrinsic Value Warrantsvestedandexpectedtovest
AggregateIntrinsicValueWarrantsvestedandexpectedtovest
0 USD
CY2021Q3 clbs Warrants Vested
WarrantsVested
21356600 shares
CY2021Q3 clbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.84
clbs Weighted Average Remaining Contractual Termwarrantoutstanding
WeightedAverageRemainingContractualTermwarrantoutstanding
P4Y7M17D
CY2021Q3 clbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
CY2021Q3 clbs Sharesvestedandexpectedtovest
Sharesvestedandexpectedtovest
21356600 shares
CY2021Q3 clbs Weighted Average Exercise Price Warrants Vested And Expected To Vest
WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
2.84
clbs Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest
WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
P4Y7M17D
CY2021Q3 clbs Weighted Average Exercise Price Warrants Exercisable
WeightedAverageExercisePriceWarrantsExercisable
2.84
clbs Weighted Average Remaining Contractual Termwarrantsvested
WeightedAverageRemainingContractualTermwarrantsvested
P4Y7M17D
CY2021Q3 clbs Aggregate Intrinsic Value Warrantsvested
AggregateIntrinsicValueWarrantsvested
0 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
773000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
229000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1639000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1090000 USD
CY2017Q1 us-gaap Grants Receivable
GrantsReceivable
12200000 USD
CY2017Q1 clbs Funding Amount Awarded
FundingAmountAwarded
8600000 USD
clbs Funding Of Grant Award Cash Received
FundingOfGrantAwardCashReceived
8200000 USD
CY2017Q2 clbs Funding Of Grant Award Cash Received
FundingOfGrantAwardCashReceived
5700000 USD
CY2017Q4 clbs Milestone Payment On Grant Award Cash Received
MilestonePaymentOnGrantAwardCashReceived
1900000 USD
CY2018Q1 clbs Progress Payment On Grant Award Cash Received
ProgressPaymentOnGrantAwardCashReceived
300000 USD
CY2019Q2 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
200000 USD
CY2020Q3 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
46000 USD
CY2021Q3 clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
0 USD
clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
0 USD
CY2020Q3 clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
300000 USD
clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
1600000 USD
CY2020Q4 clbs Market Capitalization Used In Net Operating Loss Analysis
MarketCapitalizationUsedInNetOperatingLossAnalysis
125000000 USD
clbs Net Operating Loss Analysis Annual Limitation
NetOperatingLossAnalysisAnnualLimitation
3000000 USD
CY2021Q2 clbs Proceeds From Sale Of Net Operating Losses Njeda Program
ProceedsFromSaleOfNetOperatingLossesNJEDAProgram
1400000 USD
CY2021Q2 clbs Proceeds From Sale Of Net Operating Losses Njeda Program Gross
ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross
1500000 USD
CY2021Q2 clbs Loss On Sale Of Net Operating Losses
LossOnSaleOfNetOperatingLosses
100000 USD

Files In Submission

Name View Source Status
0000320017-21-000108-index-headers.html Edgar Link pending
0000320017-21-000108-index.html Edgar Link pending
0000320017-21-000108.txt Edgar Link pending
0000320017-21-000108-xbrl.zip Edgar Link pending
clbs-20210930.htm Edgar Link pending
clbs-20210930.xsd Edgar Link pending
clbs-20210930_cal.xml Edgar Link unprocessable
clbs-20210930_def.xml Edgar Link unprocessable
clbs-20210930_htm.xml Edgar Link completed
clbs-20210930_lab.xml Edgar Link unprocessable
clbs-20210930_pre.xml Edgar Link unprocessable
clbs-ex311_20210930xq3.htm Edgar Link pending
clbs-ex32_20210930q3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending